Jab1/CSN5 induces the cytoplasmic localization and degradation of RUNX3

Journal of Cellular Biochemistry

Volumn 107, Issue 3, 2009, Pages 557-565

  Kim, Jang Hyun ^a   Choi, Joong Kook ^a   Cinghu, Senthilkumar ^a   Jang, Ju Won ^a   Lee, You Soub ^a   Li, Ying Hui ^a   Goh, Yun Mi ^a   Chi, Xin Zi ^a   Lee, Kyeong Sook ^a   Wee, Heejun ^a   Bae, Suk Chul ^a  

^a Chungbuk National University   (South Korea)

Author keywords

CK2; CSN; Jab1; RUNX; Tumor suppressor

Indexed keywords

COP9 SIGNALOSOME; JUN ACTIVATION DOMAIN BINDING PROTEIN 1; PROTEASOME; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; EMBRYO; FEMALE; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STABILITY;

ACTIVE TRANSPORT, CELL NUCLEUS; CELL NUCLEUS; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 3 SUBUNIT; CYTOPLASM; HELA CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PEPTIDE HYDROLASES; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 66749137635     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22157     Document Type: Article

References (45)

1. Bae SC, Lee YH. 2006. Phosphorylation, acetylation and ubiquitination: The molecular basis of RUNX regulation. Gene 366:58-66. (Pubitemid 43199594)
2. Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, Pollmann C, Dubiel W. 2001. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 20:1630-1639. (Pubitemid 32299400)
3. Bianchi E, Denti S, Granata A, Bossi G, Geginat J, Villa A, Rogge L, Pardi R. 2000. Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity. Nature 404:617-621. (Pubitemid 30205061)
4. Chi TH, Wan M, Zhao K, Taniuchi I, Chen L, Littman DR, Crabtree GR. 2002. Reciprocal regulation of CD4/CD8 expression by SWI/SNF-like BAF complexes. Nature 418:195-199. (Pubitemid 34773775)
5. Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, Li QL, Kim HR, Cha EJ, Lee YH, Kaneda A, Ushijima T, Kim WJ, Ito Y, Bae SC. 2005. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol 25:8097-8107. (Pubitemid 41263003)
6. Eswarakumar VP, Horowitz MC, Locklin R, Morriss-Kay GM, Lonai P. 2004. A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc Natl Acad Sci USA 101:12555-12560. (Pubitemid 39122062)
7. Fukumoto A, Tomoda K, Yoneda-Kato N, Nakajima Y, Kato JY. 2006. Depletion of Jab1 inhibits proliferation of pancreatic cancer cell lines. FEBS Lett 580:5836-5844. (Pubitemid 44584281)
8. Goto A, Niki T, Moriyama S, Funata N, Moriyama H, Nishimura Y, Tsuchida R, Kato JY, Fukayama M. 2004. Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma. Pathol Int 54:675-681. (Pubitemid 39297292)
9. Huang J, Yuan H, Lu C, Liu X, Cao X, Wan M. 2007. Jab1 mediates protein degradation of the rad9-rad1-hus1 checkpoint complex. J Mol Biol 371:514-527. (Pubitemid 47048285)
10. Inoue K, Ozaki S, Shiga T, Ito K, Masuda T, Okado N, Iseda T, Kawaguchi S, Ogawa M, Bae SC, Yamashita N, Itohara S, Kudo N, Ito Y. 2002. Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons. Nat Neurosci 5:946-954.
11. Inoue K, Ozaki S, Ito K, Iseda T, Kawaguchi S, Ogawa M, Bae SC, Yamashita N, Itohara S, Kudo N, Ito Y. 2003. Runx3 is essential for the target-specific axon path finding of trkc-expressing dorsal root ganglion neurons. Blood Cells Mol Dis 30:157-160. (Pubitemid 36539357)
12. Ito Y. 2004. Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 23:4198-4208.
13. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK, Han HC, Ito T, Teh M, Yeoh KG, Ito Y. 2005a. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 65:7743-7750. (Pubitemid 41297249)
14. Ito Y, Yoshida H, Nakamura Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Kakudo K, Miyauchi A. 2005b. Expression of Jun activation domain-binding protein 1 and p27 (Kip1) in thyroid medullary carcinoma. Pathology 37:216-219. (Pubitemid 40942981)
15. Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, Li QL, Yang JO, Ito Y, Bae SC. 2005. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res 65:9347-9354. (Pubitemid 41508002)
16. Kim HJ, Nam SH, Park HS, Ryoo HM, Kim SY, Cho TJ, Kim SG, Bae SC, Kim IS, Stein JL, van Wijnen AJ, Stein GS, Lian JB, Choi JY. 2006. Four novel RUNX2 mutations including a splice donor site result in the cleidocranial dysplasia phenotype. J Cell Physiol 207:114-122.
17. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764. (Pubitemid 27516178)
18. Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret FX. 2003. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res 63:2977-2981. (Pubitemid 36667172)
19. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, Sukumar S. 2006. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66:6512-6520. (Pubitemid 44085605)
20. Lee B, Thirunavukkarasu K, Zhou L, Pastore L, Baldini A, Hecht J, Geoffroy V, Ducy P, Karsenty G. 1997. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet 16:307-310. (Pubitemid 27280218)
21. Levanon D, Bettoun D, Harris-Cerruti C, Woolf E, Negreanu V, Eilam R, Bernstein Y, Goldenberg D, Xiao C, Fliegauf M, Kremer E, Otto F, Brenner O, Lev-Tov A, Groner Y. 2002. The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J 21:3454-3463. (Pubitemid 34760577)
22. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y. 2002. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109:113-124. (Pubitemid 34327521)
23. Look AT. 1997. E2A-HLF chimeric transcription factors in pro-B cell acute lymphoblastic leukemia. Curr Top Microbiol Immunol 220:45-53. (Pubitemid 27141595)
24. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JH, Owen MJ, Mertelsmann R, Zabel BU, Olsen BR. 1997. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 89:773-779. (Pubitemid 27516180)
25. Niini T, Kanerva J, Vettenranta K, Saarinen-Pihkala UM, Knuutila S. 2000. AML1 gene amplification: A novel finding in childhood acute lymphoblastic leukemia. Haematologica 85:362-366. (Pubitemid 30318508)
26. Osato M, Ito Y. 2005. Increased dosage of the RUNX1/AML1 gene: A third mode of RUNX leukemia? Crit Rev Eukaryot Gene Expr 15:217-228.
27. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T, Suzushima H, Takatsuki K, Kanno T, Shigesada K, Ito Y. 1999. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood 93:1817-1824. (Pubitemid 29128481)
28. Osato M, Yanagida M, Shigesada K, Ito Y. 2001. Point mutations of the RUNx1/AML1 gene in sporadic and familial myeloid leukemias. Int J Hematol 74:245-251. (Pubitemid 33760078)
29. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ. 1997. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765-771. (Pubitemid 27516179)
30. Pockwinse SM, Rajgopal A, Young DW, Mujeeb KA, Nickerson J, Javed A, Redick S, Lian JB, van Wijnen AJ, Stein JL, Stein GS, Doxsey SJ. 2006. Microtubule-dependent nuclear-cytoplasmic shuttling of Runx2. J Cell Physiol 206:354-362. (Pubitemid 43062803)
31. Quack I, Vonderstrass B, Stock M, Aylsworth AS, Becker A, Brueton L, Lee PJ, Majewski F, Mulliken JB, Suri M, Zenker M, Mundlos S, Otto F. 1999. Mutation analysis of core binding factor A1 in patients with cleidocranial dysplasia. Am J Hum Genet 65:1268-1278. (Pubitemid 30460377)
32. Richardson KS, Zundel W. 2005. The emerging role of the COP9 signalosome in cancer. Mol Cancer Res 3:645-653. (Pubitemid 43042994)
33. Shintani S, Li C, Mihara M, Hino S, Nakashiro K, Hamakawa H. 2003. Skp2 and Jab1 expression are associated with inverse expression of p27(KIP1) and poor prognosis in oral squamous cell carcinomas. Oncology 65:355-362. (Pubitemid 38064948)
34. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, Loh M, Felix C, Roy DC, Busque L, Kurnit D, Willman C, Gewirtz AM, Speck NA, Bushweller JH, Li FP, Gardiner K, Poncz M, Maris JM, Gilliland DG. 1999. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23:166-175. (Pubitemid 29455388)
35. Speck NA, Gilliland DG. 2002. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2:502-513. (Pubitemid 37328932)
36. Subramaniam MM, Chan JY, Soong R, Ito K, Ito Y, Yeoh KG, Salto-Tellez M, Putti TC. 2009. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat 113:113-121.
37. Tomoda K, Kubota Y, Kato J. 1999. Degradation of the cyclin-dependent- kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398:160-165. (Pubitemid 129623118)
38. Tomoda K, Kubota Y, Arata Y, Mori S, Maeda M, Tanaka T, Yoshida M, Yoneda-Kato N, Kato JY. 2002. The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J Biol Chem 277:2302-2310. (Pubitemid 34968817)
39. Uhle S, Medalia O, Waldron R, Dumdey R, Henklein P, Bech-Otschir D, Huang X, Berse M, Sperling J, Schade R, Dubiel W. 2003. Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. EMBO J 22: 1302-1312. (Pubitemid 36362694)
40. van Wijnen AJ, Stein GS, Gergen JP, Groner Y, Hiebert SW, Ito Y, Liu P, Neil JC, Ohki M, Speck N. 2004. Nomenclature for Runt-related (RUNX) proteins. Oncogene 23:4209-4210. (Pubitemid 38758585)
41. Wan M, Cao X, Wu Y, Bai S, Wu L, Shi X, Wang N, Cao X. 2002. Jab1 antagonizes TGF-beta signaling by inducing Smad4 degradation. EMBO Rep 3:171-176. (Pubitemid 34213496)
42. Wei N, Deng XW. 2003. The COP9 signalosome. Annu Rev Cell Dev Biol 19:261-286. (Pubitemid 37487350)
43. Woolf E, Xiao C, Fainaru O, Lotem J, Rosen D, Negreanu V, Bernstein Y, Goldenberg D, Brenner O, Berke G, Levanon D, Groner Y. 2003. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci USA 100:7731-7736. (Pubitemid 36760038)
44. Xirodimas DP, Saville MK, Bourdon JC, Hay RT, Lane DP. 2004. Mdm2- mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118:83-97. (Pubitemid 38902816)
45. Yoshida M, Horinouchi S. 1999. Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export. Ann NY Acad Sci 886:23-36.